Intellia Therapeutics（NTLA）今日夜盘股价大跌5.06%，引起了市场的广泛关注。
消息面上，该公司宣布将启动一项承销式公开增发计划，拟出售总值1.5亿美元的普通股。此举通常会稀释现有股东的权益，是导致股价承压的直接原因之一。杰富瑞集团、高盛与花旗集团将共同担任此次发行的联席账簿管理人。
此外，尽管该公司今日早间公布了其基因编辑疗法Lonvoguran Ziclumeran针对遗传性血管水肿的3期临床试验积极结果，数据显示该疗法在六个月内将肿胀发作次数减少了87%，但市场反应却相对平淡。分析指出，鉴于该疗法是一次性高成本疗法，市场对其要求很高，股市反应反映了市场预期失准，这进一步加剧了股价的下跌压力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.